CASI Pharmaceuticals IncCASI Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The Disclosure score covers seventeen United Nations Sustainable Development Goals including: 'Quality Education', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'. The article contains a questions and answers section about CASI Pharmaceuticals Inc. Alternative companies in the rating industry group for CASI Pharmaceuticals Inc are shown.

CASI Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.1; made up of an environmental score of 2.0, social score of 2.7 and governance score of 4.6.

SDG Transparency Score for CASI Pharmaceuticals Inc 

3.1

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for CASI Pharmaceuticals Inc 
2.0

Environmental

2.7

Social

4.6

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1733Timber Pharmaceuticals Inc
3.2
Medium
1733Zhejiang Jiuzhou Pharmaceutical Co Ltd
3.2
Medium
1760CASI Pharmaceuticals Inc
3.1
Medium
1760Anygen Co Ltd
3.1
Medium
1760AptaBio Therapeutics Inc
3.1
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does CASI Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did CASI Pharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has CASI Pharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is CASI Pharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does CASI Pharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does CASI Pharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for CASI Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Sorry!

Failed to process!